Clinical trial
Safety and Dose Study of Peramivir for Influenza Treatment
NCT00297050 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00297050 |
|---|---|
| Title | Safety and Dose Study of Peramivir for Influenza Treatment |
| Official title | A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Intravenous Peramivir in Healthy Subjects |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Drug |
| Interventions | Peramivir |
| Enrollment | 100 |
| Start date | Feb 23, 2006 |
| Primary completion | Nov 14, 2006 |
| Completion | Nov 14, 2006 |
| First posted | Feb 27, 2006 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: